BioSig Allowed First Key U.S. Patent Claims for its PURE EP System

BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, siad the U.S. Patent Office has allowed 33 patent claims covering its PURE EP System. The patent application number 16/271,462 entitled “System and Methods to Visually Align Signals Using Delay,” has not yet been published. 

The allowed claims address a system for visualizing signals such as low amplitude cardiac signals during an ablation procedure in the presence of noise. Specifically, the allowed claims address a novel way to solve a key technological need of how to synchronize the processing and display of multiple signals in near real-time. 
 
“We are pleased with this patent allowance, as we believe that this patent will provide BioSig with broad protection for our advanced PURE EP System. We have filed three additional Track One patent applications related to our omnibus and foundational patent application from May 8, 2018, and we expect to receive decisions on additional key patent allowances soon that, if allowed, will further establish our proprietary position around our biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace,” stated Kenneth L. Londoner, founder, chairman and CEO of BioSig Technologies Inc.
 
The PURE EP System is indicated as a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data.
 
Previously, BioSig announced that it successfully conducted first patient cases using its PURE EP System at the Texas Cardiac Arrhythmia Institute in Austin; Greenville Memorial Hospital in Greenville, S.C.; and Indiana University School of Medicine. These initial experiences suggested improved cardiac signal detection and fidelity.
 
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Led by a management team and a Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP System, a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System in August 2018.